



Applications of Gene Therapy in Dentistry: A Review Article

Karthika Nair¹ Amitha Ramesh Bhat¹

¹Department of Periodontology, A B Shetty Memorial Institute of Dental Sciences, NITTE Deemed to be University, Mangaluru, Karnataka, India

Address for correspondence: Karthika Nair, Postgraduate Student, A B Shetty Memorial Institute of Dental Sciences, NITTE Deemed to be University, Mangaluru 575018, Karnataka, India (e-mail: karthikanair2297@gmail.com).

J Health Allied Sci^{NU} 2023;13:445–452.

Abstract

Gene therapy promises to possess a good prospect in bridging the gap between dental applications and medicine. The dynamic therapeutic modalities of gene therapy have been advancing rapidly. Conventional approaches are being revamped to be more comprehensive and pre-emptive, which could do away with the need for surgery and medicine altogether. The complementary base sequences known as genes convey the instructions required to manufacture proteins. The oral cavity is one of the most accessible locations for the therapeutic intervention of gene therapy for several oral tissues. In 1990, the first significant trial of gene therapy was overseen to alleviate adenosine deaminase deficiency. The notion of genetic engineering has become increasingly appealing as a reflection of its benefits over conventional treatment modalities. An example of how this technology may alter dentistry is the implementation of gene therapy for dental and oral ailments. The objective of this article is to examine the effects of gene therapy on the field of dentistry, periodontology and implantology. Furthermore, the therapeutic factors of disease therapy, minimal invasion, and appropriate outcome have indeed been taken into consideration.

Keywords

- ▶ gene therapy
- ▶ applications
- ▶ dentistry
- ▶ periodontology
- ▶ recent advances

Introduction

The future of gene therapy seems optimistic for bridging the gap between the realms of clinical dentistry and medicine. The goal of gene therapy is to generate functioning proteins by replacing the aberrant genes with their suitable analogs. Data suggest that underlying illnesses including malignancies, viral diseases, genetic abnormalities, and autoimmune disorders can be treated with gene therapy to prevent, mitigate, or perhaps cure them.¹ Researchers are striving to eradicate ailments at their very roots in research institutions all around the world. They are attempting to alter the genes that cause diseases rather than seeking for medications to treat ailments. Gene therapy is the approach used to do this. New gene-transfer technologies, methods,

approaches, and perspectives have emerged over time. The term “gene therapy,” that was initially used to refer to “genetic replacement treatment” in the early 1980s, has now outgrown its intended definition and is now used to allude to any process that involves some sort of gene transfer.² Furthermore, the heterogeneous origins of periodontal disease encompass microbial challenge and diverse host immune responses that are determined by genetic and environmental determinants.^{3–5} In the first two steps in the process of gene therapy, human genetic code for the therapeutic is usually an attenuated carrier or vector, the protein is first cleaved and then put into its genome. The second stage involves introducing the modified vector to the intended human cells, which release the DNA sequence that is incorporated into a chromosome. The cells

article published online
January 20, 2023

DOI <https://doi.org/10.1055/s-0042-1759711>.
ISSN 2582-4287.

© 2023. The Author(s).

This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (<https://creativecommons.org/licenses/by/4.0/>)
Thieme Medical and Scientific Publishers Pvt. Ltd., A-12, 2nd Floor, Sector 2, Noida-201301 UP, India




Fig. 1 In vivo and ex vivo gene transfer.

with the new genetic design eventually produce the requisite therapeutic proteins as soon as the gene is “switched on” at the appropriate region.^{1,6,7} Somatic and germ line gene therapies are the two principal phases of gene therapy, respectively.⁸ Depending on the vector’s delivery method, gene transfer can be achieved by either of two methods: ex vivo gene transfer, which involves injecting the genetically engineered vector into cultured tissue cells prior to actually transferring the altered tissues into the body, or in vivo gene transfer, which involves directly injecting genetically engineered vectors into the patient^{7,9} (→ Fig. 1).

Applications in Dentistry

The significant development has been made innumerable applications of gene therapy in dentistry.¹⁰ This is shown in → Fig. 2.

Salivary Glands

A major salivary gland’s primary excretory ducts are retroductally cannulated as part of a gene therapy for salivary glands. This may lead to the synthesis of a protein that is therapeutic for cells^{11,12} or can cause secretions to enter the circulation or saliva.^{13,14} A wide range of genes, including those producing hormones,^{15,16} an antibacterial agent,¹⁷ membrane proteins,^{18,19} transcription factors,²⁰ protease inhibitors,²¹ a protein-regulating apoptosis,²² and numerous nonmammal “reporter proteins,” are applied for salivary glands.^{23–25}

Sjogren’s syndrome (SS) is an autoimmune disorder. It is basically characterized by dry eyes and dry mouth. The syndrome frequently coexist with other immune system disorder including lupus and rheumatoid arthritis. Given this circumstance, a broad paradigm for creating innovative protein and more recently gene-based treatments for several autoimmune illnesses, including SS, has evolved. This method that we employ, which involves a biological component that boosts Th2 activities and inhibits Th1 cells, is probably effective for treatment.²⁶ Interleukin-10 or vasoactive intestinal peptide, for example,




Fig. 2 Applications of gene therapy in dentistry.

are forms of anti-inflammatory cytokines whose transfer might result in a reduction in the production of proinflammatory cytokines, protecting salivary glycoproteins (SGs) and maintaining their secretory function.²⁷

Bone Repair

Bones have a good potential for regeneration and healing and can be amended, in contrast to other dental hard tissues (such as enamel and dentin).^{28,29} Ex vivo techniques have been employed in dentistry to transfer the genes that code for bone morphogenetic proteins.^{30,31} Bone morphogenetic proteins are recognized inducers of ectopic and orthotopic bone development. Bone fractures and traumas frequently heal without leaving scars. But bone healing and remodeling might be difficult in circumstances with pathological fractures or significant bone deformities.^{32–35} The robust mitogen known as platelet-derived growth factor (PDGF) is yet another that is crucial for wound healing. The biological effects of PDGF are antiapoptotic in nature and affect cell migration, proliferation, and the production of extracellular matrix. The growth arrest gene halts its activity (gas gene). The development of the bioactive PDGF gene has enabled us to circumvent the growth arrest gene’s inhibitory effects, which are crucial for wound healing.³⁶ In conjunction to the *CBFA1* gene, which is vital in cell differentiation and bone sialoprotein gene expression during bone repair and regeneration, the bone sialoprotein is a significant noncollagenous protein implicated in bone healing.³⁷

Carcinomas

Cancers of the oral cavity, paranasal sinuses, larynx, pharynx, and head and neck skin are all covered by the category of squamous cell carcinoma of the head and neck (SCCHN). It is deemed to be the sixth most prevalent cancer in the world.³² In preclinical and clinical trials for squamous cell carcinoma,

a unique gene therapy strategy that preferentially multiplies within tumor cells and lyses them has been thoroughly investigated. For the therapy of malignancies lacking p53 activity, ONYX-015 (d11520), an E1B 55kD gene-deleted adenovirus, has been created.³⁸ Patients with recurrent/refractory squamous cell carcinoma can safely administer ONYX-015 through intratumoral injection. However, when this particular type of gene therapy was administered alone, there was very limited evidence of antitumor efficacy.^{39,40} There were significant objective responses, including a high percentage of complete responses, in a phase II study of intratumoral ONYX-015 injection with cisplatin and 5-fluorouracil in patients with recurrent SCCN. In contrast to all noninjected tumors treated with chemotherapy alone, none of the responsive tumors had progressed by 6 months. Tumor-selective viral replication and necrosis induction were seen in tumor samples taken after therapy, but there was no obvious link between the presence of p53 mutations in the tumor and the clinical outcome.⁴¹ These findings corroborate the paucity of a bystander interaction and illustrate the significance of creating systemic administration agents.

“Suicide” Gene Therapy

“Suicide” gene therapy entails inserting a gene that permits a prodrug to transform into an active cytotoxic drug into a cell. Herpes simplex virus thymidine kinase is the method that has been investigated the most (HSV-TK). This gene produces a viral enzyme that converts ganciclovir into a monophosphate form, which intracellular enzymes then further phosphorylate into an active triphosphate substance that stops DNA synthesis.⁴²

Orofacial Pain

Orofacial discomfort is pain experienced in the face, head, and neck's soft and hard tissues region. Because of their intricacy and the unclear processes behind their etiology and pathogenesis, many orofacial pain syndromes, especially those that are chronic, may be particularly challenging to identify and treat.^{43–48} They range from those with a clearly identifiable cause (such as trigeminal postherpetic neuralgia and posttraumatic trigeminal neuropathic pain) to those that may be idiopathic (such as burning mouth syndrome, persistent idiopathic facial pain, and persistent idiopathic dentoalveolar pain), as well as those that manifest as a symptom of a known chronic disorder or disease. Moreover, if the acute disease is not adequately treated in a timely and suitable manner, ~20% of acute pains might develop into a chronic pain state.^{49–53} Analgesics^{54–56} and sedatives⁵⁷ are typically used in pain treatment. Gene therapy is being researched to effectively facilitate chronic pain effectively by reducing the consumption of medications that pose the threat of systemic toxicity, opioid addiction, and other detrimental consequences.⁵⁸ At the moment, gene therapy is mostly used in animal models to treat pain. Recently, it was shown that expressing the human preproenkephalin gene via a herpes simplex vector reduced trigeminal pain in a mouse model.⁵⁹ In the future, enhanced vector gene

systems may make gene therapy more effective in treating pain syndromes including trigeminal neuralgia and temporomandibular joint diseases.^{60,61}

Tooth Repair and Regeneration

Known for decades as an organ with strong reparative and regeneration capabilities is the pulp. Dental pulp cells have the ability to terminally develop into cells that mimic odontoblasts to generate reparative dentine. The enhanced odontogenic differentiation capacity of pulp cells transfected with growth/differentiation factor 11 has been observed in tests of gene therapeutic approaches.⁶² It has also been researched how to stimulate the differentiation of pulp cells into odontoblast-like cells using the synthetic glucocorticoid dexamethasone and growth factors (GFs) such as BMP2.^{63,64} When given directly to the exposed tooth pulp during *in vivo* gene therapy, genes that stimulate dentine development improve the ability of tissues such as the dentine pulp complex to recuperate.⁶⁵ Dental pulp stem cells may also offer a novel alternative cell population for heart,⁶⁶ bone,^{67,68} muscle,⁶⁹ brain,⁷⁰ and tooth repair and/or regeneration,^{71–73} pertaining to *in vivo* empirical evidences in animals. Notably, a patient underwent the first clinical application for dental pulp stem cell-assisted alveolar bone restoration last year with success.⁷⁴

Orthodontic Tooth Movement

Alveolar corticotomy surgery is an adjunctive treatment that can cut the length of orthodontic treatment in half.^{75,76} Alternative treatments must be considered, nevertheless, because of the short-accelerated mobility time and the high morbidity rates associated with this type of surgery. Bone resorption and apposition are two biological processes that are intimately related to tooth movement (TM). The ratio of the receptor activator of nuclear factor- κ B (RANKL) to the osteoprotegerin (OPG) is intimately related to the biomolecular pathways of osteoclast activation (OPG).⁷⁷ Corticotomy-assisted malocclusion treatment has been demonstrated empirically to reduce TM phases due to the enhanced pace of bone remodeling caused by the so-called regional acceleratory phenomenon.^{78,79} Taking into account all the information, we hypothesize that sustained overexpression of RANKL will not only increase osteoclastogenesis and bone resorption and selectively activate osteoclast but will also cause tooth movement (TM) under force to accelerate over time rather than just at the start of therapy, in contrast to the corticotomy procedure. It was proposed that local RANKL gene transfer would be a helpful strategy for shifting ankylosed teeth as well as for shortening orthodontic therapy. Local OPG gene transfer, in contrast to RANKL, reduced tooth displacement after 21 days of force application by around 50%. As a result of shorter treatment times and better outcomes, orthodontic therapy will undergo a paradigm change.⁸⁰ Additionally, gene therapy has demonstrated potential outcomes in reducing orthodontic TM discomfort. Future gene therapy therapeutic solutions that may be administered to manage the discomfort associated with orthodontic TM may be developed as a consequence of more study.⁵⁶




Fig. 3 Applications of gene therapy in Periodontics.

Applications of Gene Therapy in Periodontics – Fig. 3

Periodontal Vaccination

When a mouse's salivary gland is subjected to plasmid DNA encoding the *Porphyromonas gingivalis* fimbrial gene, the salivary gland produces fimbrial protein locally in the salivary gland tissue that further leads to the production of specific serum and salivary immunoglobulin G (IgG) and immunoglobulin A antibodies. The *P. gingivalis* that was generated might be negated, prohibiting it from aiding to the growth of plaque (– Fig. 3).

Furthermore, investigators have discovered in rats that vaccination with genetically manipulated *Streptococcus gordonii* vectors expressing *P. gingivalis* fimbrial antigen is effective at preventing *P. gingivalis*-associated periodontitis.⁸¹

Hemagglutinin, an integral to maintaining of *P. gingivalis*' lethality, has been detected, cloned, and amplified in *Escherichia coli*. In Fischer rats infected with *P. gingivalis*, the subcutaneous administration of recombinant hemagglutinin B (rHag B) culminated in serum IgG antibody and the synthesis of interleukin-2 (IL-2), IL-10, and IL-4, which offered protection against *P. gingivalis*-induced bone loss.⁸²

Biofilm Antibiotic Resistance

According to research, bacteria which form biofilms are up to 1,000 times more resistant to antibiotics than their natural counterparts, making them challenging to regulate.

Recently, Mah et al revealed the *Pseudomonas aeruginosa* RA14 strain gene *ndvB*,⁸² which expresses for the glycosyl-transferase requisite for the biosynthesis of periplasmic glucans.

Electroporation for Alveolar Bone Remodeling

When confronted to elements involving mechanical strain and inflammation, periodontal tissue aggressively revamps by synthesizing a wide range of chemicals. Predictable alveolar redevelopment has really been demonstrated utilizing in vivo transfer of the *LacZ* gene (containing code for a

multitude of remodeling molecules) into periodontal ligament (PDL) and leveraging plasmid DNA as a vector combined with transient transfection (electric impulse) to transfer the gene into cell.⁸³

Tight Adherence Gene for Control of Periodontal Disease Progression

A significant first component in the establishment of localized aggressive periodontitis is the invasion of target tissue by a periodontal pathogen such as *Actinobacillus actinomycetemcomitans*. *Actinobacillus actinomycetemcomitans* has been revealed to require a “tight adherence” in to attach and be virulent. Researchers have isolated a mutant strain defective in the “tight adherence gene” that could really predictably influence the progression of periodontal disease by inhibiting *A. actinomycetemcomitans* recruitment and pathogenesis.⁸⁴

Antimicrobial Gene Therapy to Control Disease Progression

Transfecting host cells with an antimicrobial peptide or protein-encoding gene is one technique for strengthening the host defense mechanism against infection.

So, according to the research, there was a robust antimicrobial activity that augmented host antimicrobial defenses when host cells were invaded in vivo with the defensin-2 (HBD-2) gene utilizing retroviral vector.⁸⁵

F. Designer Drug therapy in treating periodontal disease⁸⁵

If the genes required for normal development are determined, “designer therapeutic interventions” that tackle one or both components of the gene can be devised. As they would only alter the gene abnormality that has been clearly recognized via genetic research, these designer therapies would be safer than the pharmaceuticals we use today.

Gene Therapy to Grow New Teeth

Dental research is hoping to be able to fabricate teeth in a laboratory so that individuals who have misplaced their tooth structure can have them implanted. These teeth would not even have nerves or blood vessels, but they would be composed of the same components as human teeth. To achieve this, researchers must determine the genes that generate the 25 regulatory proteins that help compensate the tooth structure. Nevertheless, there may also be numerous of other genes instructing the body where, when, and when to develop a specific tooth.⁸⁵

Gene Therapy to Promote Oral Implant Osseointegration

There is immense potential for periodontal regenerative medicine in the use of osteogenic GFs, such as PDGF, to replenish tooth-supporting and peri-implant alveolar bone in preclinical studies models⁸⁶⁻⁹⁰ and in early human trials.^{91,92} The drug fragility at the administering site is one rationale why the consequences of these interventions are constrained in terms of regeneration and dependability.

So, using gene therapy to modulate osteogenic GF release and bioavailability affords prospects for tissue engineering of osseous defects.⁹³ Our team has recently seen the possibility of utilizing genetic recombination to rejuvenate the cementum and alveolar bone around teeth, together with the alveolar bone associated with dental implant fixtures.^{36,94}

These investigations have already shown that the use of genome editing for bone regeneration does have a significant amount of potential.

As contrary to continuous PDGF administration in vitro, gene transfer has been demonstrated to boost gingival fibroblast, PDL, and tooth-lining cell (cementoblast) mitogenesis and proliferation. Furthermore, PDGF has also shown remarkable results in fostering bone repair surrounding teeth and dental treatment. This application's key goal is to assess novel PDGF gene transfer regenerative medicine methodologies in animal models with the long-term intent of human use.^{95,96}

Recent Advances of Gene Therapy

To convey genes more accurately and effectively for combatting maladies that are not amenable to treatment with a single stimulus-responsive gene carrier, numerous multiple stimulus-responsive nanocarriers have been developed.⁹⁷ Systems that adapt to multiple stimuli make use of multiple stimulus responses. For illustrate, two polymeric micelles featuring sulfonamide-functionalized poly(N-isopropylacrylamide) substrates were used to generate pH/temperature sympathetic nanocarriers.⁹⁸ Both sulfadimethoxine surface-functionalized and sulfamethazine surface-functionalized micelles exhibited higher intracellular uptake when activated with a proof-of-concept antiproliferative drug under mildly acidic conditions (pH 6.8) at temperatures well above their lower critical solution temperatures. Both forms of microemulsions could be employed as an intracellular pH and temperature-responsive medicament or gene delivery system.

Future Directions in Periodontal Regeneration

The domain of periodontal care is severely affected by tissue engineering. Bioengineering attempts to devise a therapeutic system to support periodontal repair are integrating cell and gene therapy to accelerate and steer periodontal wound closure into a more predictable regenerative trajectory. However, there are still several challenges. Numerous emerging systems with the potential to augment tissue-healing biology have been highlighted in the content of this assessment. How to improve the utilization of cells and genes delivered to a passive or compliant environment where there is context for the kind of cell desired, but in which certain molecular signals are given to stimulate normal cell function, remains a major challenge today. Identifying cell sources and clinically relevant cell numbers, integrating multiple cells into existing tissue matrices, and striving to achieve bioactivity of tissue equivalents using an expanded repertoire of biomaterials are all obstacles to overcome that the field of tissue engineering still needs to

transcend. The practical and regulatory requirements to deploy these technologies in the health care setting continue to pose major challenges to the domains of cell and gene transfer.

Conclusion

Despite the enormous interest in this area, there have been no dentine repair clinical studies and only a limited number of periodontal disease therapy clinical applications. Cell-based bioengineering and material sciences must specify the prerequisites for producing reliable, repeatable goods that are inspected for efficacy and safety. In-depth research is being done on gene therapy for a variety of biomedical and dental uses. Gene therapy is anticipated to be a very helpful tool for the management of oral illnesses and improving the prognosis and quality of life in light of the exponential growth in instances of oral squamous cell carcinoma and periodontal disorders. The positive results of recent human clinical studies have given physicians confidence that gene therapy may soon advance to practical applications. Future clinical orthodontics will benefit from this sort of biological research because, like other biomedical disciplines, it must adapt to new developments in biological applications to improve clinical outcomes and treatment effectiveness. Finding solutions to these problems that prevent gene therapy from becoming a common therapeutic option should be the focus of research. In the near future, it is anticipated that this will be able to get over the challenges posed by gene therapy's clinical uses. With more study and advancements, dentists will take on a new role as "gene therapists," excelling at treating mouth cancer and mending alveolar bone abnormalities in clinical settings.

Conflict of Interest

None declared.

References

- Misra S. Human gene therapy: a brief overview of the genetic revolution. *J Assoc Physicians India* 2013;61(02):127-133
- Wood KJ, Fry J. Gene therapy: potential applications in clinical transplantation. *Expert Rev Mol Med* 1999;1-20
- Haffajee AD, Socransky SS. Microbial etiological agents of destructive periodontal diseases. *Periodontol* 2000 1994;5:78-111
- Page RC, Kornman KS. The pathogenesis of human periodontitis: an introduction. *Periodontol* 2000 1997;14:9-11
- Hill AB. The environment and disease: association or causation? *Proc R Soc Med* 1965;58:295-300
- Prabhakar AR, Paul JM, Basappa N. Gene therapy and its implications in dentistry. *Int J Clin Pediatr Dent* 2011;4(02):85-92
- Karthikeyan BV, Pradeep AR. Gene therapy in periodontics: a review and future implications. *J Contemp Dent Pract* 2006;7(03):83-91
- Wirth T, Parker N, Ylä-Herttua S. History of gene therapy. *Gene* 2013;525(02):162-169
- Romano G, Pacilio C, Giordano A. Gene transfer technology in therapy: current applications and future goals. *Stem Cells* 1999;17(04):191-202
- Baum BJ, O'Connell BC. The impact of gene therapy on dentistry. *J Am Dent Assoc* 1995;126(02):179-189

- 11 Baum BJ, Zheng C, Cotrim AP, et al. Transfer of the AQP1 cDNA for the correction of radiation-induced salivary hypofunction. *Biochim Biophys Acta* 2006;1758(08):1071–1077
- 12 Kok MR, Yamano S, Lodde BM, et al. Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjögren's syndrome. *Hum Gene Ther* 2003;14(17):1605–1618
- 13 Voutetakis A, Bossis I, Kok MR, et al. Salivary glands as a potential gene transfer target for gene therapeutics of some monogenic endocrine disorders. *J Endocrinol* 2005;185(03):363–372
- 14 Wang J, Cawley NX, Voutetakis A, et al. Partial redirection of transgenic human growth hormone secretion from rat salivary glands. *Hum Gene Ther* 2005;16(05):571–583
- 15 He X, Goldsmith CM, Marmary Y, et al. Systemic action of human growth hormone following adenovirus-mediated gene transfer to rat submandibular glands. *Gene Ther* 1998;5(04):537–541
- 16 Goldfine ID, German MS, Tseng HC, et al. The endocrine secretion of human insulin and growth hormone by exocrine glands of the gastrointestinal tract. *Nat Biotechnol* 1997;15(13):1378–1382
- 17 O'Connell BC, Xu T, Walsh TJ, et al. Transfer of a gene encoding the anticandidal protein histatin 3 to salivary glands. *Hum Gene Ther* 1996;7(18):2255–2261
- 18 Delporte C, O'Connell BC, He X, et al. Increased fluid secretion after adenoviral-mediated transfer of the aquaporin-1 cDNA to irradiated rat salivary glands. *Proc Natl Acad Sci U S A* 1997;94(07):3268–3273
- 19 Delporte C, Redman RS, Baum BJ. Relationship between the cellular distribution of the alpha(v)beta3/5 integrins and adenoviral infection in salivary glands. *Lab Invest* 1997;77(02):167–173
- 20 Lillibridge CD, O'Connell BC. In human salivary gland cells, overexpression of E2F1 overcomes an interferon- γ - and tumor necrosis factor- α -induced growth arrest but does not result in complete mitosis. *J Cell Physiol* 1997;172(03):343–350
- 21 Xiong W, Chao J, Chao L. Expression and localization of human kallistatin in rat submandibular gland after intracapsular gene injection. *Biochem Biophys Res Commun* 1997;231(02):494–498
- 22 Fleck M, Zhang HG, Kern ER, Hsu HC, Muller-Ladner U, Mountz JD. Treatment of chronic sialadenitis in murine model of Sjogren's syndrome by local FasI gene transfer. *Arthritis Rheum* 2001;44:964–973
- 23 Barka T, Van der Noen HM. Retrovirus-mediated gene transfer into salivary glands in vivo. *Hum Gene Ther* 1996;7(05):613–618
- 24 Kagami H, Atkinson JC, Michalek SM, et al. Repetitive adenovirus administration to the parotid gland: role of immunological barriers and induction of oral tolerance. *Hum Gene Ther* 1998;9(03):305–313
- 25 Wang S, Baum BJ, Kagami H, Zheng C, O'Connell BC, Atkinson JC. Effect of clodronate on macrophage depletion and adenoviral-mediated transgene expression in salivary glands. *Journal of oral pathology & medicine*. 1996 Apr;28(04):145–151
- 26 Firestein GS. VIP: a very important protein in arthritis. *Nat Med* 2001;7(05):537–538
- 27 Lodde BM, Mineshiba F, Wang J, et al. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome. *Ann Rheum Dis* 2006;65(02):195–200
- 28 Kneser U, Schaefer DJ, Polykandriotis E, Horch RE. Tissue engineering of bone: the reconstructive surgeon's point of view. *J Cell Mol Med* 2006;10(01):7–19
- 29 Zafar MS, Khurshid Z, Almas K. Oral tissue engineering progress and challenges. *Tissue Engineering and Regenerative Medicine* 2015 Dec;12(06):387–397
- 30 Franceschi RT, Wang D, Krebsbach PH, Rutherford RB. Gene therapy for bone formation: in vitro and in vivo osteogenic activity of an adenovirus expressing BMP7. *J Cell Biochem* 2000;78(03):476–486
- 31 Krebsbach PH, Gu K, Franceschi RT, Rutherford RB. Gene therapy-directed osteogenesis: BMP-7-transduced human fibroblasts form bone in vivo. *Hum Gene Ther* 2000;11(08):1201–1210
- 32 Chisholm E, Bapat U, Chisholm C, Alusi G, Vassaux G. Gene therapy in head and neck cancer: a review. *Postgrad Med J* 2007;83(986):731–737
- 33 Luo J, Sun MH, Kang Q, et al. Gene therapy for bone regeneration. *Curr Gene Ther* 2005;5(02):167–179
- 34 Kawabata M, Imamura T, Miyazono K. Signal transduction by bone morphogenetic proteins. *Cytokine Growth Factor Rev* 1998;9(01):49–61
- 35 Kirker-Head CA. Potential applications and delivery strategies for bone morphogenetic proteins. *Adv Drug Deliv Rev* 2000;43(01):65–92
- 36 Jin Q, Anusaksathien O, Webb SA, Printz MA, Giannobile WV. Engineering of tooth-supporting structures by delivery of PDGF gene therapy vectors. *Mol Ther* 2004;9(04):519–526
- 37 Boulefour W, Juignet L, Bouet G, et al. The role of the SIBLING, Bone Sialoprotein in skeletal biology - contribution of mouse experimental genetics. *Matrix Biol* 2016;52-54:60–77
- 38 Heise CC, Williams AM, Xue S, Propst M, Kirn DH. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. *Cancer Res* 1999;59(11):2623–2628
- 39 Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. *J Clin Oncol* 2001;19(02):289–298
- 40 Kirn D, Hermiston T, McCormick F. ONYX-015: clinical data are encouraging. *Nat Med* 1998;4(12):1341–1342
- 41 Khuri FR, Nemunaitis J, Ganly I, et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. *Nat Med* 2000;6(08):879–885
- 42 Matthews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. *Rev Infect Dis* 1988;10(3, suppl 3):S490–S494
- 43 Lipton JA, Ship JA, Larach-Robinson D. Estimated prevalence and distribution of reported orofacial pain in the United States. *J Am Dent Assoc* 1993;124(10):115–121
- 44 Arendt-Nielsen L, Graven-Nielsen T, Sessle BJ. Mechanisms underlying extraterritorial and widespread sensitization: from animal to chronic pain. In: Graven-Nielsen T, Arendt-Nielsen L, eds. *Musculoskeletal Pain: Basic Mechanisms & Implications*. Washington, DC: Wolters Kluwer Health; 2015:417–436
- 45 Macfarlane TV. Epidemiology of orofacial pain. In: Sessle BJ, ed. *Orofacial Pain: Recent Advances in Assessment, Management, and Understanding of Mechanisms*. Washington, DC: IASP Press; 2014:33–52
- 46 Svensson P, Baad-Hansen L, Drangsholt M, Jaaskelainen S. Neurosensory testing for assessment, diagnosis, and prediction of orofacial pain. In: Sessle BJ, ed. *Orofacial Pain: Recent Advances in Assessment, Management, and Understanding of Mechanisms*. Washington, DC: IASP Press; 2014:143–164
- 47 Slade GD, Greenspan JD, Fillingim RB, Maixner W, Sharma S, Ohrbach R. Overlap of five chronic pain conditions: temporomandibular disorders, headache, back pain, irritable bowel syndrome, and fibromyalgia. *J Oral Facial Pain Headache* 2020;34:s15–s28
- 48 Sessle BJ, Baad-Hansen L, Exposto F, Svensson P. Orofacial pain. In: Lynch M, Craig K, Peng P, eds. *Clinical Pain Management: A Practical Guide*. 2nd ed. New York, NY: Wiley-Blackwell; 2021; in press
- 49 Lynch ME, Campbell F, Clark AJ, et al. A systematic review of the effect of waiting for treatment for chronic pain. *Pain* 2008;136(1-2):97–116
- 50 Chapman CR, Vierck CJ. The transition of acute postoperative pain to chronic pain: an integrative overview of research on mechanisms. *J Pain* 2017;18(04):359.e1–359.e38
- 51 Pak DJ, Yong RJ, Kaye AD, Urman RD. Chronification of pain: mechanisms, current understanding, and clinical implications. *Curr Pain Headache Rep* 2018;22(02):9

- 52 Glare P, Aubrey KR, Myles PS. Transition from acute to chronic pain after surgery. *Lancet* 2019;393(10180):1537–1546
- 53 Khan J, Zusman T, Wang Q, Eliav E. Acute and chronic pain in orofacial trauma patients. *Dent Traumatol* 2019;35(06):348–357
- 54 Romero-Reyes M, Uyanik JM. Orofacial pain management: current perspectives. *J Pain Res* 2014;7:99–115
- 55 Camu F, Vanlersberghe C. Pharmacology of systemic analgesics. *Baillieres Best Pract Res Clin Anaesthesiol* 2002;16(04):475–488
- 56 Long H, Wang Y, Jian F, Liao LN, Yang X, Lai WL. Current advances in orthodontic pain. *Int J Oral Sci* 2016;8(02):67–75
- 57 Gazal G, Fareed WM, Zafar MS, Al-Samadani KH. Pain and anxiety management for pediatric dental procedures using various combinations of sedative drugs: a review. *Saudi Pharm J* 2016;24(04):379–385
- 58 Jain KK. Gene therapy for pain. *Expert Opin Biol Ther* 2008;8(12):1855–1866
- 59 Ma F, Wang C, Yoder WE, et al. Efficacy of herpes simplex virus vector encoding the human preproenkephalin gene for treatment of facial pain in mice. *J Oral Facial Pain Headache* 2016;30(01):42–50
- 60 Tzabazis AZ, Klukinov M, Feliciano DP, Wilson SP, Yeomans DC. Gene therapy for trigeminal pain in mice. *Gene Ther* 2014;21(04):422–426
- 61 Kuboki T, Nakanishi T, Kanyama M, et al. Direct adenovirus-mediated gene delivery to the temporomandibular joint in guinea-pigs. *Arch Oral Biol* 1999;44(09):701–709
- 62 Nakashima M, Iohara K, Ishikawa M, et al. Stimulation of reparative dentin formation by ex vivo gene therapy using dental pulp stem cells electrotransfected with growth/differentiation factor 11 (Gdf11). *Hum Gene Ther* 2004;15(11):1045–1053
- 63 Alliot-Licht B, Bluteau G, Magne D, et al. Dexamethasone stimulates differentiation of odontoblast-like cells in human dental pulp cultures. *Cell Tissue Res* 2005;321(03):391–400
- 64 Iohara K, Nakashima M, Ito M, Ishikawa M, Nakasima A, Akamine A. Dentin regeneration by dental pulp stem cell therapy with recombinant human bone morphogenetic protein 2. *J Dent Res* 2004;83(08):590–595
- 65 Nakashima M, Iohara K, Zheng L. Gene therapy for dentin regeneration with bone morphogenetic proteins. *Curr Gene Ther* 2006;6(05):551–560
- 66 Nosrat IV, Widenfalk J, Olson L, Nosrat CA. Dental pulp cells produce neurotrophic factors, interact with trigeminal neurons in vitro, and rescue motoneurons after spinal cord injury. *Dev Biol* 2001;238(01):120–132
- 67 Gandia C, Armiñan A, García-Verdugo JM, et al. Human dental pulp stem cells improve left ventricular function, induce angiogenesis, and reduce infarct size in rats with acute myocardial infarction. *Stem Cells* 2008;26(03):638–645
- 68 Graziano A, d'Aquino R, Laino G, et al. Human CD34+ stem cells produce bone nodules in vivo. *Cell Prolif* 2008;41(01):1–11
- 69 Graziano A, d'Aquino R, Laino G, Papaccio G. Dental pulp stem cells: a promising tool for bone regeneration. *Stem Cell Rev* 2008;4(01):21–26
- 70 Kerkis I, Ambrosio CE, Kerkis A, et al. Early transplantation of human immature dental pulp stem cells from baby teeth to golden retriever muscular dystrophy (GRMD) dogs: local or systemic? *J Transl Med* 2008;6:35
- 71 Onyekwelu O, Seppala M, Zoupa M, Cobourne MT. Tooth development: 2. Regenerating teeth in the laboratory. *Dent Update* 2007;34(01):20–22, 25–26, 29
- 72 Cordeiro MM, Dong Z, Kaneko T, et al. Dental pulp tissue engineering with stem cells from exfoliated deciduous teeth. *J Endod* 2008;34(08):962–969
- 73 Nedel F, André DdeA, de Oliveira IO, et al. Stem cells: therapeutic potential in dentistry. *J Contemp Dent Pract* 2009;10(04):90–96
- 74 d'Aquino R, De Rosa A, Lanza V, et al. Human mandible bone defect repair by the grafting of dental pulp stem/progenitor cells and collagen sponge biocomplexes. *Eur Cell Mater* 2009;18:75–83
- 75 Wilcko MT, Wilcko WM, Pulver JJ, Bissada NF, Bouquot JE. Accelerated osteogenic orthodontics technique: a 1-stage surgically facilitated rapid orthodontic technique with alveolar augmentation. *J Oral Maxillofac Surg* 2009;67(10):2149–2159
- 76 Iino S, Sakoda S, Ito G, Nishimori T, Ikeda T, Miyawaki S. Acceleration of orthodontic tooth movement by alveolar corticotomy in the dog. *Am J Orthod Dentofacial Orthop* 2007;131(04):448.e1–448.e8
- 77 Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. *Cell* 1998;93(02):165–176
- 78 Frost HM. The regional acceleratory phenomenon: a review. *Henry Ford Hospital Medical Journal*. 1983;31(01):3–9
- 79 Burstone CJ. The biophysics of bone remodelling during orthodontics-optimal force considerations. In: Norton LA, Burstone CJ, eds. *The Biology of Tooth Movement*. Boca Raton: CRC Press; 1989:321–334
- 80 Baum BJ, Kok M, Tran SD, Yamano S. The impact of gene therapy on dentistry: a revisiting after six years. *J Am Dent Assoc* 2002;133(01):35–44
- 81 Katz J, Black KP, Michalek SM. Host responses to recombinant hemagglutinin B of *Porphyromonas gingivalis* in an experimental rat model. *Infect Immun* 1999;67(09):4352–4359
- 82 Mah TF, Pitts B, Pellock B, Walker GC, Stewart PS, O'Toole GA. A genetic basis for *Pseudomonas aeruginosa* biofilm antibiotic resistance. *Nature* 2003;426(6964):306–310
- 83 Tsuchiya S, Chiba M, Kishimoto K, Nakamura H, Mitani H. Gene transfer into periodontal tissue by in vivo electroporation. *INJOURNAL OF DENTAL RESEARCH* 2002 Mar 1 (Vol. 81, pp. A452-A452). 1619 DUKE ST, ALEXANDRIA, VA 22314-3406 USA: INT AMER ASSOC DENTAL RESEARCH IADR/AADR
- 84 Schreiner HC, Sinatra K, Kaplan JB, et al. Tight-adherence genes of *Actinobacillus actinomycetemcomitans* are required for virulence in a rat model. *Proc Natl Acad Sci U S A* 2003;100(12):7295–7300
- 85 Cathy AJ. Teeth-We're going to grow them back. 2005
- 86 Becker W, Lynch SE, Lekholm U, et al. A comparison of ePTFE membranes alone or in combination with platelet-derived growth factors and insulin-like growth factor-I or demineralized freeze-dried bone in promoting bone formation around immediate extraction socket implants. *J Periodontol* 1992;63(11):929–940
- 87 Rutherford RB, Niekrash CE, Kennedy JE, Charette MF. Platelet-derived and insulin-like growth factors stimulate regeneration of periodontal attachment in monkeys. *J Periodontol Res* 1992;27(4 Pt 1):285–290
- 88 Giannobile WV, Finkelman RD, Lynch SE. Comparison of canine and non-human primate animal models for periodontal regenerative therapy: results following a single administration of PDGF/IGF-I. *J Periodontol* 1994;65(12):1158–1168
- 89 Park JB, Matsuura M, Han KY, et al. Periodontal regeneration in class III furcation defects of beagle dogs using guided tissue regenerative therapy with platelet-derived growth factor. *J Periodontol* 1995;66(06):462–477
- 90 Giannobile WV, Hernandez RA, Finkelman RD, et al. Comparative effects of platelet-derived growth factor-BB and insulin-like growth factor-I, individually and in combination, on periodontal regeneration in *Macaca fascicularis*. *J Periodontol Res* 1996;31(05):301–312
- 91 Howell TH, Fiorellini JP, Paquette DW, Offenbacher S, Giannobile WV, Lynch SE. A phase I/II clinical trial to evaluate a combination of recombinant human platelet-derived growth factor-BB and recombinant human insulin-like growth factor-I in patients with periodontal disease. *J Periodontol* 1997;68(12):1186–1193
- 92 Nevins M, Giannobile WV, McGuire MK, et al. Platelet-derived growth factor stimulates bone fill and rate of attachment level gain: results of a large multicenter randomized controlled trial. *J Periodontol* 2005;76(12):2205–2215

- 93 Ramseier CA, Abramson ZR, Jin Q, Giannobile WV. Gene therapeutics for periodontal regenerative medicine. *Dent Clin North Am* 2006;50(02):245–263, ix
- 94 Dunn CA, Jin Q, Taba M Jr, Franceschi RT, Bruce Rutherford R, Giannobile WV. BMP gene delivery for alveolar bone engineering at dental implant defects. *Mol Ther* 2005;11(02):294–299
- 95 Giannobile WV, Lee CS, Tomala MP, Tejada KM, Zhu Z. Platelet-derived growth factor (PDGF) gene delivery for application in periodontal tissue engineering. *J Periodontol* 2001;72(06):815–823
- 96 Zhu Z, Lee CS, Tejada KM, Giannobile WV. Gene transfer and expression of platelet-derived growth factors modulate periodontal cellular activity. *J Dent Res* 2001;80(03):892–897
- 97 Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. *Mol Cancer* 2019;18(01):60
- 98 Cyphert EL, von Recum HA, Yamato M, Nakayama M. Surface sulfonamide modification of poly(N-isopropylacrylamide)-based block copolymer micelles to alter pH and temperature responsive properties for controlled intracellular uptake. *J Biomed Mater Res A* 2018;106(06):1552–1560